EP4119569A1 — Conjugated antisense compounds for use in therapy
Assigned to Ionis Pharmaceuticals Inc · Expires 2023-01-18 · 3y expired
What this patent protects
Provided herein is an oligomeric compound for use in treating or preventing a disease or condition in a human, wherein the treatment comprises administering not more than 300mg of the oligomeric compound to the human during a dosing period of four weeks, wherein the anion form of…
USPTO Abstract
Provided herein is an oligomeric compound for use in treating or preventing a disease or condition in a human, wherein the treatment comprises administering not more than 300mg of the oligomeric compound to the human during a dosing period of four weeks, wherein the anion form of the oligomeric compound has the following chemical structure:
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.